Clinical trial risk in castration-resistant prostate cancer: Immunotherapies show promise

BJU International

Volumn 113, Issue 5 B, 2014, Pages

  Tenuta, Alessandro ^a   Klotz, Laurence ^b   Parker, Jayson L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Attrition rate; Castration resistant prostate cancer; Clinical trial risk; Hormone refractory prostate cancer; Immunotherapies

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; AFLIBERCEPT; AGATOLIMOD; BELINOSTAT; BORTEZOMIB; CEDIRANIB; CUSTIRSEN; DIAZEPINOMICIN; ENTINOSTAT; GANITUMAB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GTI 2040; IMATINIB; IPILIMUMAB; ISOSORBIDE; NIVOLUMAB; NY ESO 1 ANTIGEN; OXG 011; PACLITAXEL; PICOPLATIN; PROSTATE SPECIFIC ANTIGEN; SEPANTRONIUM BROMIDE; SIPULEUCEL T; TANESPIMYCIN; THALIDOMIDE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZIBOTENTAN;

ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; TOTAL QUALITY MANAGEMENT; ATTRITION RATE; CLINICAL TRIAL RISK; IMMUNOTHERAPIES; IMMUNOTHERAPY;

ATTRITION RATE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL RISK; HORMONE REFRACTORY PROSTATE CANCER; IMMUNOTHERAPIES;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK ASSESSMENT;

EID: 84902352095     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12309     Document Type: Article

References (21)

1. Grenet O. Significance of the human genome sequence to drug discovery. The Pharmacogenomics Journal 2001; 1: 11-2
2. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009; 8: 959-68
3. st century: new drug approvals in the first decade 2000-2009. Clin Pharmacol Ther 2011; 89: 183-8
4. Harris G. Federal research centre will help develop medicines. The New York Times: Money and Policy. Published January 22 2011. Available at: http://www.nytimes.com/2011/01/23/health/policy/23drug.html. Accessed January 2011
5. Honig P, Lalonde R. The economics of drug development: a grim reality and role of clinical pharmacology. Clin Pharmacol Ther 2010; 87: 247-51
6. DiMasi JA, Feldman L, Seckler A et al. Trends in risks associated with new drug development: success rates of investigational drugs. Clin Pharmacol Ther 2010; 87: 272-7
7. Parker JL, Kohler JC. The success rate of new drug development in clinical trials: Crohn's disease. J Pharm Pharm Sci 2010; 13: 191-7
8. National Cancer Institute. SEER (Surveillance Epidemiology and End Results) Stat Fact Sheets: Prostate. Available at: http://seer.cancer.gov/ statfacts/html/prost.html. Accessed November 2010
9. FDA approves a new indication for Taxotere-Prostate Cancer. FDA News Release.May 19 2004. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2004/ucm108301.htm. Accessed December 2010
10. FDA approves a cellular immunotherapy for men with advanced prostate cancer. FDA News Release. April 29 2010. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm. Accessed November 2010
11. Prostate cancer: Sipuleucel-T Commentary. Available at: http://fdaapprovalsreview.com/Provenge.html. Accessed March 2011
12. Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer-second line after docetaxel. National Horizon Scanning Centre, University of Birmingham, National Institute for Health Research. Available at: http://www.haps.bham.ac.uk/publichealth/horizon/outputs/documents/2009/jan-apr/ Cabazitaxel.pdf. Accessed March 2011
13. Osborne BJW, Kaul R, Parker JL. Drug development risk in HIV-1 clinical trials: the effect of drug class. J Pharm Health Serv Res 2011; 2: 211-6
14. Parker JL, Zhang ZY, Buckstein R. Clinical trial risk in Non-Hodgkin's lymphoma: endpoint and target selection. J Pharm Pharm Sci 2011; 14: 227-35
15. Jayasundara K, Keystone E, Parker JL. Clinical trial risk in moderate to severe rheumatoid arthritis patients. J Rheumatol 2012; 39: 2066-70
16. Vogelzang NJ et al. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23: 4563 (N16s June 1 Supplement)
17. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995; 58: 1-14
18. DiMasi JA, Hansen RW, Grabowski HG et al. Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-42
19. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008; 83: 227-30
20. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85 (Pubitemid 36279392)
21. Parker JL, Lushina N, Bahl P, Petrella T, Dent R, Lopes G. Clinical trial risk in metastatic breast cancer: the limitations of biomarkers. Breast Cancer Res Treat 2012; 136: 179-85